| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(01)00059-7 |
| P698 | PubMed publication ID | 11348714 |
| P2093 | author name string | Li T | |
| Takeda N | |||
| Miyamura T | |||
| P2860 | cites work | Pinocytosis by epithelium associated with lymphoid follicles in the bursa of fabricius, appendix, and Peyer's patches. An electron microscopic study | Q54073608 |
| Hepatitis E and long-term antibody status | Q59830076 | ||
| Incidence and severity of viral hepatitis in pregnancy | Q59830166 | ||
| Induction of Oral Tolerance in the Primed Immune System: Influence of Antigen Persistence and Adjuvant Form | Q63409743 | ||
| Intestinal M Cells: A Pathway for Entry of Reovirus into the Host | Q72884912 | ||
| Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission | Q33547143 | ||
| Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer's patches--a personal and historical perspective | Q33669560 | ||
| Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 | ||
| Norwalk virus vaccines: challenges and progress | Q33914464 | ||
| Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route | Q34055652 | ||
| Oral tolerance | Q34058680 | ||
| Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures | Q34085608 | ||
| Specific adherence of Escherichia coli (strain RDEC-1) to membranous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit | Q35202097 | ||
| Successful passive and active immunization of cynomolgus monkeys against hepatitis E | Q35838428 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Expression and self-assembly of empty virus-like particles of hepatitis E virus | Q35894748 | ||
| Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering | Q36778446 | ||
| Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization | Q41203441 | ||
| Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes | Q41632254 | ||
| Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. | Q43965189 | ||
| Hepatitis E virus transmission to a volunteer | Q44391700 | ||
| Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus | Q44502533 | ||
| Recombinant Norwalk virus-like particles given orally to volunteers: phase I study | Q45748767 | ||
| Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type | Q45794396 | ||
| Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology | Q45806646 | ||
| Epidemic non-A, non-B hepatitis in patients from Pakistan. | Q45943389 | ||
| Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. | Q51187990 | ||
| P433 | issue | 25-26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis E virus | Q5731737 |
| hepatitis E | Q326643 | ||
| P304 | page(s) | 3476-3484 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice | |
| P478 | volume | 19 |
| Q52655590 | Challenges in creating a vaccine to prevent hepatitis E. |
| Q40507463 | Characteristics and Functions of HEV Proteins |
| Q44902179 | Chimeric hepatitis E virus-like particle as a carrier for oral-delivery |
| Q38606892 | Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit |
| Q33717736 | Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice |
| Q40587927 | DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration |
| Q37589024 | Designing, Construction and Expression of a Recombinant Fusion Protein Comprising the Hepatitis E Virus ORF2 and Rotavirus NSP4 in the Baculovirus Expression System |
| Q35110575 | Detection and localization of rabbit hepatitis e virus and antigen in systemic tissues from experimentally intraperitoneally infected rabbits |
| Q56588500 | Development of new hepatitis E vaccines |
| Q42006154 | Encapsulation and delivery of plasmid DNA by virus-like nanoparticles engineered from Macrobrachium rosenbergii nodavirus |
| Q34045644 | Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus |
| Q38396830 | Expression and characterization of hepatitis E virus-like particles and non-virus-like particles from insect cells |
| Q37278231 | Hepatitis E vaccine |
| Q35826279 | Hepatitis E vaccines: progress and prospects |
| Q34669741 | Hepatitis E: an overview |
| Q34334086 | Hepatitis E: an overview and recent advances in vaccine research. |
| Q40131145 | Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles |
| Q100294872 | Immunization of human hepatitis E viruses conferred protection against challenge by a camel hepatitis E virus |
| Q45404731 | Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice |
| Q38461061 | Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies |
| Q35838661 | Mucosal immunity: overcoming the barrier for induction of proximal responses. |
| Q37854151 | Pathogenetic elements of hepatitis E and animal models of HEV infection |
| Q36610885 | Production of hepatitis E virus-like particles presenting multiple foreign epitopes by co-infection of recombinant baculoviruses |
| Q44689542 | Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles |
| Q34786990 | Recent advances in mucosal vaccines and adjuvants |
| Q34399421 | Recombinant vaccines for hepatitis E. |
| Q34485189 | Spatial configuration of hepatitis E virus antigenic domain |
| Q36739811 | The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase |
| Q36590168 | The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects? |
| Q37881208 | Toward the development of a hepatitis E vaccine |
| Q42014293 | Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis |
| Q36601830 | Vaccines for viral and parasitic diseases produced with baculovirus vectors |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development |
| Q37666808 | Virus-like particles as a vaccine delivery system: myths and facts |
Search more.